CD36 as a double-edged sword in cancer

被引:6
|
作者
Jiang, Muwei [1 ]
Karsenberg, Renske [1 ]
Bianchi, Frans [1 ]
Bogaart, Geert van den [1 ]
机构
[1] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Immunol, Nijenborgh 7, Groningen, Netherlands
基金
欧洲研究理事会;
关键词
CD36; Cancer; oxLDL; Lipid metabolism; Tumor immunology; LOW-DENSITY-LIPOPROTEIN; FATTY-ACID UPTAKE; PANCREATIC ADENOCARCINOMA; TUMOR MICROENVIRONMENT; METABOLIC ADAPTATION; BINDING-SITE; RECEPTOR; CELLS; DEFICIENCY; ACTIVATION;
D O I
10.1016/j.imlet.2023.12.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The membrane protein CD36 is a lipid transporter, scavenger receptor, and receptor for the antiangiogenic protein thrombospondin 1 (TSP1). CD36 is expressed by cancer cells and by many associated cells including various cancer-infiltrating immune cell types. Thereby, CD36 plays critical roles in cancer, and it has been reported to affect cancer growth, metastasis, angiogenesis, and drug resistance. However, these roles are partly contradictory, as CD36 has been both reported to promote and inhibit cancer progression. Moreover, the mechanisms are also partly contradictory, because CD36 has been shown to exert opposite cellular effects such as cell division, senescence and cell death. This review provides an overview of the diverse effects of CD36 on tumor progression, aiming to shed light on its diverse pro- and anti-cancer roles, and the implications for therapeutic targeting.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [1] Chemotherapy: a double-edged sword in cancer treatment
    Nafiseh Behranvand
    Farzad Nasri
    Reza Zolfaghari Emameh
    Pouria Khani
    Asieh Hosseini
    Johan Garssen
    Reza Falak
    Cancer Immunology, Immunotherapy, 2022, 71 : 507 - 526
  • [2] The role of necroptosis in cancer: A double-edged sword?
    Qin, Xia
    Ma, Dan
    Tan, Ye-xiong
    Wang, Hong-yang
    Cai, Zhenyu
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 259 - 266
  • [3] Chemotherapy: a double-edged sword in cancer treatment
    Behranvand, Nafiseh
    Nasri, Farzad
    Emmameh, Zolfaghari
    Khani, Pouria
    Hosseini, Asieh
    Garssen, Johan
    Falak, Reza
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 507 - 526
  • [4] Notch and cancer: a double-edged sword
    Koch, U.
    Radtke, F.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (21) : 2746 - 2762
  • [5] Diablo: A Double-Edged Sword in Cancer?
    Arbiser, Jack L.
    MOLECULAR THERAPY, 2018, 26 (03) : 678 - 679
  • [6] Inflammasomes in cancer: a double-edged sword
    Kolb, Ryan
    Liu, Guang-Hui
    Janowski, Ann M.
    Sutterwala, Fayyaz S.
    Zhang, Weizhou
    PROTEIN & CELL, 2014, 5 (01) : 12 - 20
  • [7] FSTL1: A double-edged sword in cancer development
    Du, Ruijuan
    Li, Kai
    Guo, Kelei
    Chen, Zhiguo
    Han, Li
    Bian, Hua
    GENE, 2024, 906
  • [8] Cancer and viruses: A double-edged sword
    Butt, Aisha Q.
    Miggin, Sinead M.
    PROTEOMICS, 2012, 12 (13) : 2127 - 2138
  • [9] Notch and cancer: a double-edged sword
    U. Koch
    F. Radtke
    Cellular and Molecular Life Sciences, 2007, 64 : 2746 - 2762
  • [10] The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer
    Cirillo, Nicola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (21)